As of 30 Sep 2025, 5 institutional investors reported holding $23,363,000 in principal (par value) of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | $23,363,000 | $18,818,473 | +$3,641 | 81.68% | 5 |
| 2025 Q2 | $23,363,000 | $17,787,228 | 76.2% | 5 | |
| 2025 Q1 | $23,363,000 | $17,777,468 | 76.14% | 5 | |
| 2024 Q4 | $23,363,000 | $18,181,290 | -$20,439 | 77.82% | 5 |
| 2024 Q3 | $23,363,000 | $17,535,188 | +$1,520,000 | 77.0% | 6 |
| 2024 Q2 | $21,363,000 | $13,668,131 | -$77,761,376 | 64.58% | 5 |
| 2024 Q1 | $146,918,494 | $90,613,439 | -$11,662,000,470 | 54.23% | 11 |
| 2023 Q4 | $170,334,654 | $86,027,205 | +$11,407,465 | 50.0% | 11 |
| 2023 Q3 | $147,861,853 | $106,877,272 | 62.06% | 11 | |
| 2023 Q2 | $147,861,853 | $112,651,752 | -$879,387 | 67.75% | 11 |
| 2023 Q1 | $176,607,744 | $150,781,059 | +$159,829 | 77.1% | 11 |
| 2022 Q4 | $157,006,126 | $129,433,751 | -$509,924 | 75.89% | 10 |
| 2022 Q3 | $91,657,126 | $83,984,443 | -$1,736,501 | 80.81% | 9 |
| 2022 Q2 | $101,389,000 | $78,918,752 | -$54,523,098 | 73.0% | 11 |
| 2022 Q1 | $160,811,700 | $146,930,092 | +$2,122,310 | 83.86% | 18 |
| 2021 Q4 | $157,667,200 | $141,128,926 | -$1,119,797 | 81.72% | 19 |
| 2021 Q3 | $161,228,700 | $131,158,902 | -$7,147,490 | 75.26% | 17 |
| 2021 Q2 | $161,123,000 | $161,965,451 | -$1,201,655 | 100.3% | 17 |
| 2021 Q1 | $162,120,500 | $168,019,191 | -$24,429,782 | 103.64% | 14 |
| 2020 Q4 | $179,189,000 | $224,437,310 | +$2,415,747 | 125.55% | 14 |
| 2020 Q3 | $177,172,000 | $212,921,099 | -$7,311,826 | 119.75% | 14 |
| 2020 Q2 | $179,672,000 | $254,147,406 | +$146,260 | 140.22% | 17 |
| 2020 Q1 | $179,520,000 | $258,406,915 | -$1,646,929 | 144.51% | 15 |
| 2019 Q4 | $180,302,000 | $258,383,194 | +$258,383,194 | 143.16% | 16 |